Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update - $40 million in non-dilutive capital drawn from Neumora’s existing facility with K2 HealthVentures
Neumora Therapeutics, Inc. a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Neumora today announced that it has drawn an additional $40 million from its existing venture debt facility with K2 HealthVentures. The additional $40 million in non-dilutive capital from this facility drawn, combined with the cash already on the Company’s balance sheet, further strengthens its financial position.
Neumora Therapeutics, Inc. a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced financial results for the third quarter ended September 30, 2025, and provided a business update. Neumora today announced that it has drawn an additional $40 million from its existing venture debt facility with K2 HealthVentures. The additional $40 million in non-dilutive capital from this facility drawn, combined with the cash already on the Company’s balance sheet, further strengthens its financial position.
Phil Secures $60 Million Growth Capital Facility from K2 HealthVentures to Accelerate AI Integration
Phil, a leading software-driven pharmaceutical commercialization platform, today announced a $60 million growth debt financing from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. The funding will accelerate the integration of artificial intelligence across Phil's platform and support continued customer expansion across a broad range of therapeutic areas.
Phil, a leading software-driven pharmaceutical commercialization platform, today announced a $60 million growth debt financing from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. The funding will accelerate the integration of artificial intelligence across Phil's platform and support continued customer expansion across a broad range of therapeutic areas.
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Neumora today announced that it has entered into a venture debt facility for up to $125 million with K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries. Under the terms of the facility, $20 million was drawn at closing, with an additional $20 million available to be drawn at Neumora’s option by December 31, 2025. The additional $85 million will be available for drawdown at Neumora's option upon the achievement of certain milestones.
Neumora today announced that it has entered into a venture debt facility for up to $125 million with K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries. Under the terms of the facility, $20 million was drawn at closing, with an additional $20 million available to be drawn at Neumora’s option by December 31, 2025. The additional $85 million will be available for drawdown at Neumora's option upon the achievement of certain milestones.
Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones
Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced the closing of a $100 million Series C financing. The financing was co-led by Double Point Ventures and DCVC Bio, with participation from new and existing investors including ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota Endowment, and other prominent life science investors.
Umoja Biopharma, Inc., the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced the closing of a $100 million Series C financing. The financing was co-led by Double Point Ventures and DCVC Bio, with participation from new and existing investors including ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota Endowment, and other prominent life science investors.
Evergreen Nephrology Raises $130 Million to Transform and Expand Access to Value-Based Kidney Care
Evergreen Nephrology, a leader in value-based kidney care, today announced it has raised $130 million in capital to expand its care model to more patients living with kidney disease. Funding was led by Rubicon Founders, Oak HC/FT and a group of existing investors, with the addition of K2 HealthVentures. Funding will fuel Evergreen's growth by enabling its expansion into new regions while implementing advanced technologies to improve clinical outcomes, streamline care delivery, and ease the administrative burden on nephrologists.
Evergreen Nephrology, a leader in value-based kidney care, today announced it has raised $130 million in capital to expand its care model to more patients living with kidney disease. Funding was led by Rubicon Founders, Oak HC/FT and a group of existing investors, with the addition of K2 HealthVentures. Funding will fuel Evergreen's growth by enabling its expansion into new regions while implementing advanced technologies to improve clinical outcomes, streamline care delivery, and ease the administrative burden on nephrologists.
Life Science Cares Boston launches Health Equity Portfolio Co-Investment Program as part of Anti-Poverty Strategy for Greater Boston
[Cambridge, MA June 3, 2024] — Life Science Cares Boston (LSC Boston), an anti-poverty nonprofit organization rooted in the life sciences, is proud to announce the launch of a new grantmaking program aimed at addressing health inequities among low-income families and communities in the Greater Boston area. K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries, has partnered with LSC Boston as the seed funder for this initiative.
[Cambridge, MA June 3, 2024] — Life Science Cares Boston (LSC Boston), an anti-poverty nonprofit organization rooted in the life sciences, is proud to announce the launch of a new grantmaking program aimed at addressing health inequities among low-income families and communities in the Greater Boston area.
Since 2016, LSC Boston has leveraged the talent, passion, and community investments of the life science industry to fight poverty and provide a platform for the city’s leading industry to make a difference in the community. Through leveraging partnerships with life science companies and executives, LSC Boston has granted nearly $10 Million to 85 nonprofits providing access to Basic Needs, Education, and Economic Opportunity.
LSC Boston is now expanding their commitment to disrupt the cycle of poverty by launching a new Health Equity program that invests in nonprofits improving health and wellness across three areas: Safe Homes & Vibrant Communities; Access to Equitable, Dignified Care; and Advocacy and Civic Wellness. Through this initiative, LSC Boston will provide crucial support to organizations delivering innovative, community-based solutions that improve health outcomes and foster vibrant, resilient communities.
K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries, has partnered with LSC Boston as the seed funder for this initiative.
“We are proud to join Life Science Cares Boston in their mission to create a healthier, more equitable Boston. K2 HealthVentures was built on the idea of ‘profit with a purpose’ and since our founding, giving back to our community and supporting underserved areas in healthcare has been core to our work,” said Parag Shah, Founding Managing Director & CEO of K2 HealthVentures. “This investment exemplifies the power of collaboration between the private sector and nonprofit organizations to address complex societal challenges. We are grateful for the opportunity to partner with Life Science Cares Boston to support our shared passion for improving outcomes for those most in need.”
In recognition of their innovative vision and commitment to disrupting the cycle of poverty in Greater Boston, K2 HealthVentures was awarded the 2024 Luke Timmerman Impact Award by Life Science Cares Boston.
“This work will be a new focus of our work at Life Science Cares Boston,” said Yvonne Spicer, EdD, Executive Director of LSC Boston. “Through this pilot program, we hope to show our ability to make a significant collective impact on health outcomes and promote social justice in our community.”
LSC Boston invites potential investors and philanthropic partners to join in this critical effort to address health inequities and create a healthier, more equitable future for all.
Nonprofit organizations interested in applying for grants can expect a transparent and structured process, with grants ranging from $15,000 to $75,000 per year, to provide unrestricted funding, awarded in two-year increments.
“The reality is that income and health are inextricably linked,” said Kelly Brawn, PhD, Head of Programs and Community Engagement at LSC Boston. “I’m incredibly proud of the impact we have and continue to make, but it is clear that we can—and therefore must—do more to disrupt the pernicious cycle of poverty. Investing in creative solutions that improve the health of our neighbors will allow us to do just that.”
From ensuring high-quality maternal health to disrupting systems that perpetuate the cycle of poverty to providing equal access to green space, this new program allows us to reach further into our community and support more of our neighbors in need.
For more information on how to apply or become a co-investor, please visit www.lifesciencecares.org/health-equity
Life Science Cares (LSC) activates the financial and human capital of the life sciences industry and partners with nonprofits to disrupt the cycle of poverty and inequality in our communities. LSC was founded to move the needle on issues of poverty, while helping companies build connections with the community and internally between employees.
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“AβOs”) for the treatment of Alzheimer’s disease (“AD”), today announced that it has entered into a senior secured loan and security agreement (the “Loan Agreement”) with K2 HealthVentures, a healthcare-focused specialty finance company.
CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“AβOs”) for the treatment of Alzheimer’s disease (“AD”), today announced that it has entered into a senior secured loan and security agreement (the “Loan Agreement”) with K2 HealthVentures, a healthcare-focused specialty finance company.
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
NEW YORK, August 14, 2023 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company.
Coherus to Acquire Surface Oncology
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surface acquisition adds two differentiated clinical stage assets to Coherus’ novel I-O pipeline: SRF388, a novel IL-27-targeted antibody currently being evaluated in Phase 2 clinical trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.
Elevation Oncology Announces Pricing of $50 Million Public Offering
NEW YORK, June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the pricing of an underwritten public offering of (i) 17,810,000 shares of its common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 4,440,000 shares of common stock and (ii) accompanying warrants to purchase one share of common stock for each share of common stock or pre-funded warrant sold. The combined offering price to the public of each share of common stock and accompanying warrant is $2.2500. The combined offering price to the public of each pre-funded warrant and accompanying warrant is $2.2499. The accompanying warrants have an exercise price of $2.25 per share, are exercisable immediately, and will expire five years following the date of issuance.
TScan Therapeutics Announces Pricing of $140 Million Public Offering
WALTHAM, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 22,989,474 shares of its voting common stock at a public offering price of $2.00 per share, and pre-funded warrants to purchase up to an aggregate of 47,010,526 shares of its common stock at a price to the public of $1.9999 per pre-funded warrant, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant.
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
CAMBRIDGE, MA, April 25, 2023 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activities. The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to microbiome therapy. Defined bacterial consortia are products of standardized composition manufactured from cell banks, bypassing the need to rely on donor fecal material of inconsistent composition.
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it has closed a private placement of redeemable preferred stock and warrants to purchase common stock to certain institutional and other accredited investors for aggregate gross proceeds to the Company of $25 million, before deducting offering expenses, which does not include any proceeds that may be received upon exercise of the warrants.
ASLAN Pharmaceuticals Announces $20m Private Placement Led by BVF Partners L.P. With The Potential to Receive up to an Additional $80m
San Mateo, California, and Singapore, February 24, 2023 – ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a definitive purchase agreement (“Purchase Agreement”) to raise gross proceeds of approximately $20 million resulting from the sale of its ordinary shares (or pre-funded warrants) and accompanying purchase warrants, at a purchase price of $0.178 per ordinary share (or the equivalent of $0.89 per American Depositary Share (“ADS”)) to BVF Partners L.P., K2 HealthVentures and certain existing investors (the “Investors”). In addition, ASLAN will have the potential to receive up to an additional $80 million if all purchase warrants being issued in connection with the Purchase Agreement are fully exercised.
Alto Neuroscience Announces $60 Million in Additional Financing
LOS ALTOS, Calif., January 30, 2023 – Alto Neuroscience Inc. today announced a $25 million equity investment by new investor, Alpha Wave Ventures. This brings Alto’s total Series B funding to approximately $60 million and total equity capital raised to approximately $100 million since the company was founded in 2019. In addition, Alto recently entered into a credit facility with K2 HealthVentures for up to $35 million, allowing access to additional capital and flexibility as the company advances its clinical-stage pipeline. Funding to date will support Alto through a total of four Phase 2 readouts with four novel drug candidates across three indications, as well as the continued evolution of Alto’s Precision Psychiatry Platform™.
89bio Provides Business Update and Outlook for 2023
SAN FRANCISCO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today provided a corporate update, including its roadmap for advancing pegozafermin in 2023.
DispatchHealth Raises More Than $330 Million to Expand Its Technology-Enabled Ecosystem of High Acuity Care in the Home
DENVER, Nov. 23, 2022 /PRNewswire/ -- DispatchHealth, the nation’s first comprehensive in-home, high acuity medical care provider, today announced it has raised more than $330 million in combined equity and debt financing. The equity round of $259 million was led by Optum Ventures, with participation from new investors Adams Street Partners, Blue Shield of California, among others, and continued support from existing investors Humana, Echo Health Ventures, Questa Capital and Oak HC/FT. K2 HealthVentures, Silicon Valley Bank and SVB Capital provided debt financing of $75 million, with up to an additional $75 million available for growth initiatives, bringing the total raised to more than $400 million.
Inari Raises $124 Million to Design Seeds for a More Sustainable Food System
CAMBRIDGE, Mass., October 4, 2022 — Inari today announced that it secured $124 million in the successful completion of its latest fundraise. Working to deliver nature-positive solutions, the SEEDesign™ company’s cumulative equity raised now totals $475 million. The investment will further advance Inari’s leading position in multiplex gene-edited seed technology, support expansion of company product development and ultimately deliver new value in the commercial seed market.
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVentures
WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that it has entered into a debt financing facility for up to $60 million with K2 HealthVentures (K2HV), a healthcare-focused specialty finance company.